In their concluding remarks, Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, express their hopes for future advancements in hepatocellular carcinoma (HCC) treatment, including cellular-based therapies, antibody-drug conjugates, and an increased focus on neoadjuvant studies.
Additional Second-Line Treatments for HCC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
Real-World Evidence on Second-Line Therapy Selection and Outcomes
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
Comorbidity Considerations for HCC Treatment
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
The Evolving Landscape of Second-Line Therapies in HCC Management
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.